• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

AZD-5069 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758572

MBS5758572 is an inhibitor targeting AZD-5069. AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79nM). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
AZD-5069, Inhibitor
Full Product Name
AZD-5069
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.63%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
476.52
Solubility
DMSO: 90mg/mL (188.87mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C18H22F2N4O5S2
SMILES
CC(Oc1cc(NS(=O)(=O)N2CCC2)nc(SCc2cccc(F)c2F)n1)C(O)CO
CAS Number
878385-84-3
Target & IC50
CXCR2: ic50 0.79nM
In Vitro
AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approximately 9.6, and adhesion molecule expression, with a pA2 of 6.9, in response to CXCL1[1]

Structure of AZD-5069, inhibitor

AZD-5069 Inhibitor – Cat# MBS5758572

Product References and Citations for AZD-5069, inhibitor

Nicholls D J, Wiley K, Dainty I, et al. Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 353(2):340-350.
Nicholls D J, Wiley K, Dainty I, et al. Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2015, 353(2):340-350.
Norman, Peter. Evidence on the identity of the CXCR2 antagonist AZD-5069[J]. Expert Opinion on Therapeutic Patents, 2013, 23(1):113-117.
Norman, Peter. Evidence on the identity of the CXCR2 antagonist AZD-5069[J]. Expert Opinion on Therapeutic Patents, 2013, 23(1):113-117.

Other Notes

Small volumes of AZD-5069, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000